Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...

Evolut showed less bioprosthetic valve dysfunction, prosthetic valve thrombosis and haemodynamic structural valve dysfunction ...

The preliminary results look promising for the Evolut for specific patients. The trial consists of mostly women, who have ...

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Medtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.

Medtronic, a leader in medical technology and Philips, a leader in health technology announced the signing of a Memorandum of Understanding (MoU) in India, to educate and train cardiologists and ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Discussions covered identifying eligible patients, increasing the number of specialized centers across Egypt’s governorates, ...